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ABStrACt
Plasma cell neoplasia is a lymphoid neoplastic proliferation of B cells. This denomination encloses multiple myeloma 
(MM), solitary bone plasmacytoma and extramedullary plasmacytoma. MM consists of a clonal proliferation of plasma 
cells based in the bone marrow, with various degrees of differentiation. Neoplastic cells usually produce great amounts 
of monoclonal light or heavy chains of immunoglobulin that can be detected in serum or urine. The disease is more 
frequently in men and the average age at diagnosis is about 60 years. The diagnosis is established by blood and urine 
exams and medullary biopsy. Patients may present renal failure, bone pain, fatigue, recurrent infections and nervous 
system dysfunction. Oral manifestations may be the first sign of MM, highlighting the importance of the dentist in the 
early diagnosis of the disease. Treatment involves mainly irradiation and chemotherapy and the prognosis is generally 
poor. This paper reports a case of a 65 years old black female who had a complaint of a painful mass in the maxilla 
that prompted a MM diagnosis.
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INtrODUCtION
Plasma cell tumors are lymphoid neoplastic proliferations 
that have been grouped among B-cell peripheral lymphomas, 
according to the classification of the European-American 
International Lymphoma Study Group (1). They can affect 
a single bone, a condition called solitary plasmacytoma; 
or may involve only soft tissues, an extramedullary plas-
macytoma. However, in approximately 95% of the cases, 
it involves several bones, when is called multiple myeloma 
(MM) (2, 3). MM is the most important symptomatic 
monoclonal gammopathy and represents approximately 
1% of all cancers, and 10% of all hematological neoplasms 
(4, 5). It is characterized by numerous abnormal plasma 
cells permeating the bone marrow and overproduction of 
monoclonal light-chain or heavy-chain immunoglobulins 
that are identifiable in serum or urine (5). The etiology re-
mains unknown, but some occupations, exposure to certain 
chemicals, overdose irradiation, viruses and genetic factors 
have been suggested as etiologic factors. The diagnosis of 
this pathology is established by histologic confirmation of 
a malignant proliferation of plasma cells, hematologic and 
biochemical findings, urine analysis and skeletal radiogra-
phic survey (3).
It occurs in all races, but rates are higher in African Ameri-
cans and lower in Asian population. This neoplasia is more 
common among patients with a mean age of about 60 years, 
and men are more affected than women (5). Symptoms fre-
quently result from lytic bone disease, anemia, renal failure 
and immunodeficiency (6). Complaints that are usually 
present at diagnosis are: bone pain (58%), fatigue (32%) and 
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weight loss (24%) (5). Treatment involves irradiation, che-
motherapy and more lately, autologous transplantation for 
young patients, and in addition, supportive measures may 
be used. Although the prognosis is generally poor, it may 
be affected by patient’s age, tumor site, renal involvement, 
and histological features (3).
CASE rEPOrt
A 65-year-old black woman was referred because of a pa-
inful maxillary mass for approximately 15 days. The patient 
was edentulous, and episodes of bleeding and pain were 
impairing the upper denture wearing. Her previous medical 
history revealed an episode of pneumonia two years earlier 
and there was no family history of cancer.
Lymphadenopathy was not observed. Intraoral examina-
tion disclosed a bluish-red swelling in the left canine area 
of  the maxilla. It had a smooth surface and measured 
approximately one cm in its maximum diameter (Figure 
1). Orthopantomogram survey was not worthwhile, while 
periapical radiograph showed a diffuse radiolucency (Figure 
2). An incisional biopsy was taken under local anesthesia. 
The histological features were sheets of atypical plasma cells 
(Figure 3). The immunohistochemistry results were positive 
for EMA and negative for L26, AE1/AE3, HMB45 and 
S100. Monoclonal staining for kappa was positive whereas 
lambda was negative establishing the diagnosis of a malig-
nant plasma-cell tumor (Figure 4). The patient was then 
referred for systemic evaluation. The serum electrophoresis 
revealed an IgG monoclonal gammopathy and bone marrow 
examination displayed more than 50% plasmocitosis. Other 
laboratorial findings were high serum level of ß-2 micro-
globulin, hypocalcemia, anemia and thrombocytopenia. 
Lactate dehydrogenase and creatinine levels were normal 
(Table 1). 
Count Results      Normal range 
Erythrocytes 2,91 milh/mm3 4,1-5,1 milh/mm3
Hemoglobin 6,9 g/dl 12-16 g/dl 
Platelets 118.000/mm3 150.000-450.000/mm3
Creatinine 1,3mg% 0,4-1,4mg% 
Calcium 8,6mg/dl 9-11 mg/dl 
Lactate dehydrogenase 104U/L 30-200 U/L 
Gama globulins 5,29g/dl 0,7-1,7g/dl 
table 1. Values of Complete Blood Count (CBC), chemistry measures and 
serum protein electrophoresis.
Fig. 1. Blue-red swelling in the left canine area of the 
maxilla.
Fig. 2. Periapical radiograph 
showing a diffuse radiolucency.
Fig. 3. Photomicrograph showing: sheets of atypical plasma cells (hematoxylin-
eosin stain). A- Original magnification X10. B- Original magnification X40.
Fig. 4. Immunohistochemistry: A- EMA (original magnification X40), 
B- Kappa (original magnification X40), C- L26 (original magnification 
X20) and D- Lambda (original magnification X40).
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There was no myeloma protein in the urine. The skeletal radio-
graphic survey showed osteoporotic lesions in skull and punch-
out osteolytic lesion in femur (Figure 5). According with these 
results, the diagnosis was MM stage IIIA (Durie and Salmon 
staging system). Oral chemotherapy included cyclophospha-
mide and prednisone. One month of chemotherapy prompted 
maxillary lesion regression (Figure 6); although the treatment 
was unsuccessful, and the patient died nine months latter.
DISCUSSION
The first well-documented case of multiple myeloma was 
reported by Samuel Solley in 1844, and the term “Multiple 
Myeloma” was introduced by J. von Rustizky in 1873 (5, 7). 
It is a progressive malignant disease of plasma cells clones in 
various stages of differentiation. Bone marrow examination 
shows a high amount of these abnormal plasma cells. In 99% 
of patients, MM is a secretory condition and overproduction 
of monoclonal immunoglobulins in serum and/or light chains 
(Bence Jones proteins) in the urine can be detected (6). 
MM is more often in patients between 50 and 80 years of age, 
with a mean age of 60 years and man are more affected than 
women (5). Systemic symptoms include bone pain and patho-
logic fracture, renal failure, hypercalcemia, weight loss, fatigue, 
weakness, shortening of the spine, fever, thrombocytopenia, 
neutropenia, diarrhea, orthostatic hypotension and infections 
(4, 8). Initial findings are bone pain in 68% of patients, anemia 
in 62%, renal insufficiency in 55%, hypercalcemia in 30%, pal-
pable liver in 21%, and palpable spleen in 5% (9). 
The oral manifestations of MM are the first sing of the 
disease in about 14% of the patients (10). They may include 
swelling, pain, numbness, bleeding, mobile teeth, xerosto-
mia, amyloid deposits, root resorption and mobility, labial 
anesthesia and jaw radiolucencies and fractures, and the 
prevalence varies from 2% to 70% (4, 6, 8, 10, 11, 12). In this 
case report, a painful swelling was the initial complaint. Al-
though mandibular and posterior lesions are more frequent 
(8), in this case, there was an anterior maxillary swelling.
Histologically, plasmacytomas exhibit monotonous proli-
feration of pure plasma cells, in various maturation stages 
(2). Immunohistochemistry stains must be done to confirm 
plasmacytoma. Up to 85% of plasma cell neoplasms are 
positive for EMA, an antibody against epithelial membrane 
antigen that recognizes the breast epithelial mucin complex. 
L26 stain, the favored “pan-B” cell antibody, represents 
CD20, which is expressed normally on mature B-cells and a 
subset of immature B-cells, follows the expression patterns 
in normal B-cell development; as a result plasmacytomas 
are usually negative for this antibody (13). Light chain 
restriction for Kappa or lambda is usually observed, and 
nearly 70% of plasma cell neoplasms are Kappa positive 
(13, 14). AE1/AE3, HMB45 and S100 immunoreactivity in 
plasmacytomas is generally considered rare and are done 
to exclude other pathologies. (15). In this case, both histo-
logical and immunohistochemistry led to the diagnosis of 
malignant plasma-cell lesion. 
The diagnosis of MM may be established by laboratorial exa-
ms, such hematologic, biochemical findings, urine analysis and 
skeletal radiographic survey (3). The diagnostic criteria for MM 
include evidence of multiple osteolytic lesions, identification of 
an atypical plasma cell population on biopsy and abnormalities 
of immunoglobulin production (Table 2) (16).
Fig. 5. Skeletal radiographic survey: osteolytic lesions in: A- skull and 
B- femur.
Fig. 6. Maxillary lesion remission after 1 month of chemotherapy.
Major criteria: 
1-Marrow plasmocytosis 30%.
2-Plasmacytoma on biopsy. 
3-M component: 
Serum IgG 3,5g/dl; IgA 2g/dl.
Urine 1g/24hours of Bence Jones protein. 
Minor criteria: 
1-Marrow plasmocytosis of 10-30%. 
2-M component present but less than in major criteria. 
3-Lytic bone lesions 
4-Reduced normal serum immunoglobulins ( 50% of normal) 
table 2. Criteria for diagnosis of plasma cell myeloma. The diagnosis 
requires a minimum of one major and one minor criterion, or 3 minor 
criteria which must include 1 and 2 criteria (14).
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Bone osteolytic lesions are frequently seen in 79% of the 
MM cases, and result from the osteoclastic activation by 
cytokines, increasing osteoclast numbers in areas invaded 
by malignant plasma cells and inhibiting bone formation 
(5). The most often involved sites are the vertebrae, skull, 
pelvic bones, ribs, humerus, and femur in this order of fre-
quency. Jaws may be involved in 30% (2, 10). The radiogra-
phic appearance of the lesions is generally of punched-out 
osteolytic lesions (60%), although generalized osteoporosis 
may also be seen (30%) (6). Radiographic examination of 
the patient revealed osteolytic lesions in femur and skull, in 
agreement with previous studies.
Laboratorial tests for MM usually reveal anemia (73%), 
trombocytopenia (5%) and normal creatinine value (52%). 
High serum levels of ß-2 microglobulin can be seen in 75% 
of the patients reflecting the tumor mass (5); it is one of 
the most powerful prognostic factors currently available 
for MM and can be used alone or in combination with 
other variables for pretreatment stratification (17). These 
laboratorial results were also seen in our patient’s exams. 
Hypercalcemia is also a regular feature, although in our 
case it was not detected. 
Serum eletrophoresis shows myeloma protein (M-protein) 
in about 93% of the patients. Approximately 70% of mye-
lomas secrete immunoglobulin G, and in addition, kappa 
light chains are more common. In our case, serum protein 
electrophoresis showed an IgG monoclonal spike. Urine 
eletrophoresis may show M-protein around 60% of  the 
patients, nevertheless no myeloma protein was detected 
in the urine of our patient (5). In nonsecretory myelomas, 
immunoglobulins can be detected within the cytoplasm of 
the malignant plasma cells but not in serum or urine (2).
Bone marrow examination levels of  10% or more of 
plasmocitosis are observed in 96% of patients. Medullary 
examination of our patient showed more than 50% plasma 
cells. The final diagnose was MM, stage IIIA (Durie and 
Salmon staging system), i.e. an active and symptomatic di-
sease without renal failure. The treatment of MM consists 
of chemotherapy. Cyclophosphamide, an alkylating agent, 
associated with prednisone were used in our case (3). The 
prognosis is generally considered poor, as show by the 
evolution in our case. The patient died 12 months after the 
diagnosis, because of the disease. In this case, a maxillary 
lesion was the first sign of MM, reinforcing the fundamental 
role of the dentist in the recognition and early diagnosis of 
systemic conditions.
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